oNKo-innate has appointed Bruce Fischer, MD, as its inaugural consulting Chief Medical Officer. Dr Fischer will direct oNKo’s clinical strategy as we progress the development of our lead molecule, oNKo-044. He brings a wealth of development experience to the role, including having guided numerous immuno-oncology agents through the clinic. Dr Fischer has held leadership positions within Bristol Myers Squibb for the past 16 years, including most recently as Vice President of Early Clinical Development (Oncology).
oNKo-044 is a next-generation cis-acting IL-12 cytokine-antibody fusion molecule that functions via a novel mechanism of action and exhibits an unprecedented therapeutic index in preclinical models. oNKo-044 was carefully designed using oNKo’s immunology platform that fuses deep computational design with in-vivo optimization to develop highly refined multi-specific immune modulators. We will be nominating our development candidate for this program in Q4-2024, prior to embarking on IND-enabling studies in 2025 and clinical development in 2026.
oNKo warmly welcomes Bruce as the newest member of the team!